US2021169905A1PendingUtilityA1
Fatty acid acetylated salicylates and their uses
Assignee: CATABASIS PHARMACEUTICALS INCPriority: Jul 8, 2008Filed: Jul 2, 2020Published: Jun 10, 2021
Est. expiryJul 8, 2028(~2 yrs left)· nominal 20-yr term from priority
C07C 235/60A61P 7/10C07C 233/18C07C 275/42C07C 233/55C07D 295/192C07C 271/28C07C 69/94A61P 1/04A61K 31/609A61P 21/00A61P 9/00A61P 9/06A61K 31/60A61P 3/10A61P 5/48A61P 25/14C07C 235/52C07D 295/182C07C 237/22A61P 29/00A61P 17/00C07C 233/49C07C 69/86A61K 31/232A61P 1/00A61P 9/10A61P 31/00A61P 13/12A61P 25/00A61P 3/00A61P 21/02A61P 27/02A61P 7/00A61P 25/16A61P 25/28A61P 3/06A61P 9/04
77
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.
Claims
exact text as granted — not AI-modified1 . A method of treating inflammation that is associated with metabolic disorder, wherein the metabolic disorder is selected from the group consisting of cardiovascular disease, arrhythmia, coronary artery disease, and hypertriglyceridimia, comprising administering to a patient in need thereof an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt, enantiomer, or stereoisomer thereof, wherein:
R 1 , R 2 , R 3 , and R 4 are each independently selected from the group consisting of H, Cl, F, CN, —NH(C 1 -C 3 alkyl), —N(C 1 -C 3 alkyl) 2 , —NH(C(O)C 1 -C 3 alkyl), —N(C(O)C 1 -C 3 alkyl) 2 , —C(O)H, —C(O)C 1 -C 3 alkyl, —C(O)OC 1 -C 3 alkyl, —C(O)NH 2 , —C(O)NH(C 1 -C 3 alkyl), —C(O)N(C 1 -C 3 alkyl) 2 , —O—C 1 -C 3 alkyl;
W 1 is NH and W 2 is selected from null, O, or NH;
- - - - represents an optional bond that when present requires that Q is null;
a and c are each independently H, CH 3 , —OCH 3 , —OCH 2 CH 3 , or C(O)OH;
b is H, CH 3 , C(O)OH, or O—Z;
d is H or C(O)OH;
each n, o, p, and q is independently 0 or 1;
each Z is H
with the proviso that there is at least one
in the compound;
each r is independently 2 or 3;
each s is independently 5 or 6;
each t is independently 0 or 1;
Q is null, C(O)CH 3 , Z
e is H or any one of the side chains of the naturally occurring amino acids;
W 3 is null, O, or —N(R)—;
R is H or C 1 -C 3 alkyl; and
T is H, C(O)CH 3 , or Z.
2 . The method of claim 1 , wherein W 2 is NH.
3 . The method of claim 2 , wherein r is 2, s is 6, t is 1, and Z is
4 . The method of claim 3 , wherein the compound is
5 . The method of claim 1 , wherein Q is Z.
6 . The method of claim 1 , wherein Q is
7 . The method of claim 1 , wherein Q is Z and Z is H.
8 . The method of claim 1 , wherein two of n, o, p, and q are each 1.
9 . The method of claim 1 , wherein r is 3, s is 5, t is 1, and Z is
10 . The method of claim 1 , wherein the compound is
11 . A method of treating inflammation that is associated with a neurodegenerative disorder selected from the group consisting of Huntington's Disease, infectious meningitis, encephalomyelitis, Parkinson's disease, and encephalitis, comprising administering to a patient in need thereof an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt, enantiomer, or stereoisomer thereof,
wherein:
R 1 , R 2 , R 3 , and R 4 are each independently selected from the group consisting of H, Cl, F, CN, —NH(C 1 -C 3 alkyl), —N(C 1 -C 3 alkyl) 2 , —NH(C(O)C 1 -C 3 alkyl), —N(C(O)C 1 -C 3 alkyl) 2 , —C(O)H, —C(O)C 1 -C 3 alkyl, —C(O)OC 1 -C 3 alkyl, —C(O)NH 2 , —C(O)NH(C 1 -C 3 alkyl), —C(O)N(C 1 -C 3 alkyl) 2 , —O—C 1 -C 3 alkyl:
W 1 is NH and W 2 is selected from null, O, or NH;
- - - - represents an optional bond that when present requires that Q is null;
a and c are each independently H, CH 3 , —OCH 3 , —OCH 2 CH 3 , or C(O)OH;
b is H, CH 3 , C(O)OH, or O—Z;
d is H or C(O)OH;
each n, o, p, and q is independently 0 or 1;
each Z is H or
with the proviso that there is at least one
in the compound;
each r is independently 2 or 3;
each s is independently 5 or 6;
each t is independently 0 or 1;
Q is null, C(O)CH 3 , Z,
e is H or any one of the side chains of the naturally occurring amino acids;
W 3 is null, O, or —N(R)—;
R is H or C 1 -C 3 alkyl; and
T is H, C(O)CH 3 , or Z.
12 . The method of claim 11 , wherein W 2 is NH.
13 . The method of claim 11 , wherein r is 2, s is 6, t is 1, and Z is
14 . The method of claim 11 , wherein the compound is
15 . The method of claim 11 , wherein Q is Z.
16 . (canceled)
17 . The method of claim 11 , wherein Q is Z and Z is H.
18 . The method of claim 11 , wherein two of n, o, p, and q are each 1.
19 . The method of claim 11 , wherein r is 3, s is 5, t is 1, and Z is
20 . The method of claim 11 , wherein the compound is
21 . A method of treating inflammation that is associated with a muscle wasting disorder selected from the group consisting of dermatomyositis, inclusion body myositis, polymyositis, and cachexia, comprising administering to a patient in need thereof an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt, enantiomer, or stereoisomer thereof,
wherein:
R 1 , R 2 , R 3 , and R 4 are each independently selected from the group consisting of H, Cl, F, CN, —NH(C 1 -C 3 alkyl), —N(C 1 -C 3 alkyl) 2 , —NH(C(O)C 1 -C 3 alkyl), —N(C(O)C 1 -C 3 alkyl) 2 , —C(O)H, —C(O)C 1 -C 3 alkyl, —C(O)OC 1 -C 3 alkyl, —C(O)NH 2 , —C(O)NH(C 1 -C 3 alkyl), —C(O)N(C 1 -C 3 alkyl) 2 , —O—C 1 -C 3 alkyl;
W 1 is NH and W 2 is selected from null, O, or NH;
- - - - represents an optional bond that when present requires that Q is null;
a and c are each independently H, CH 3 , —OCH 3 , —OCH 2 CH 3 , or C(O)OH;
b is H, CH 3 , C(O)OH, or O—Z;
d is H or C(O)OH;
each n, o, p, and q is independently 0 or 1;
each Z is H or
with the proviso that there is at least one
in the compound;
each r is independently 2 or 3;
each s is independently 5 or 6;
each t is independently 0 or 1;
Q is null, C(O)CH 3 , Z,
e is H or any one of the side chains of the naturally occurring amino acids;
W 3 is null, O, or —N(R)—;
R is H or C 1 -C 3 alkyl; and
T is H, C(O)CH 3 , or Z.
22 - 30 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.